Compare SHEN & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHEN | CERT |
|---|---|---|
| Founded | 1902 | 2008 |
| Country | United States | United States |
| Employees | 1041 | N/A |
| Industry | Telecommunications Equipment | Retail: Computer Software & Peripheral Equipment |
| Sector | Telecommunications | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 880.2M | 860.9M |
| IPO Year | 1994 | 2020 |
| Metric | SHEN | CERT |
|---|---|---|
| Price | $16.16 | $4.59 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $26.00 | $11.67 |
| AVG Volume (30 Days) | 356.4K | ★ 3.0M |
| Earning Date | 05-01-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.73% | N/A |
| EPS Growth | N/A | ★ 87.50 |
| EPS | N/A | ★ N/A |
| Revenue | $357,854,000.00 | ★ $418,838,000.00 |
| Revenue This Year | $7.12 | $4.18 |
| Revenue Next Year | N/A | $5.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 9.08 | 8.75 |
| 52 Week Low | $9.67 | $4.45 |
| 52 Week High | $17.35 | $13.88 |
| Indicator | SHEN | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 54.77 | 26.03 |
| Support Level | $12.66 | N/A |
| Resistance Level | $17.13 | $6.47 |
| Average True Range (ATR) | 0.96 | 0.34 |
| MACD | -0.06 | -0.18 |
| Stochastic Oscillator | 81.36 | 6.23 |
Shenandoah Telecommunications Co with its subsidiaries, provides various broadband communication products and services via its wireless, cable, fiber optic, and fixed wireless networks to customers in the Mid-Atlantic United States. The company operates through one business unit: Broadband. The broadband segment provides broadband Internet, video, and voice services to residential and commercial customers. The broadband segment generates the vast majority of the company's revenue, with the bulk of sales flowing from residential and small, and medium businesses within the broadband unit.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.